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A ~eries of new epoxysuccinyl peplides were devil|ned and syntl~©sized to develop a s~eifl¢ inhibitor of ¢alhep~in B, Of these compounds, N-(L.3- 
tr(uu-ethoxyearbo)~yloxiran¢.2.¢arbonyll.L.isoleucyI-L.prolinc (compound CA.0~0] and N.(L.~.lrans.propylearbamoyloxirane-2.earbonyl).L. 
i~oloueyI.L.proline tcompound CA.0741 were lhe mosl polcnt and q~¢ctl~c inhibitors of eathepstn B in vitro, The carboxyl lroup of prolinc and 
the (:thyl ester llroup or n.propylamide lift, up in the oxiran¢ rtn[I were necessary, the ethyl ©~ter ilroup or the n.propylamtt|e ~roup bein8 particularly 
effective fur distinlluishlnl$ eatltepsin B from other cystcine prot¢inases such as cathepsins L and H, and ealpains, 
Epox~'~ucciayI peptide; Cathepsin B: Cys~einc proteinase; Specific inhibitor 
I. INTRODUCTION 
Cathepsins B, H and L, and calpains, well- 
characterized cysteine proteinases in mammalian cells. 
play major roles in intracellular protein breakdown [1] 
and in the degradation of extracellular-matrix proteins 
such as collagen and elastin [2,3]. Specific inhibitors of 
these proteinases would be useful in studying their in- 
dividual biological roles. Hanada et  al, discovered a
new type of irreversible inhibitor of cysteine proteinases 
[4]. The first inhibitor of this type was isolated from 
Aspergiilus japonicus, identified as N-(L-3.trans- 
carbo×yoxirane-2-carbonyl)-L-leucine-4-guanidinobu- 
tylamide, and named E-64 for simplicity. It inhibits 
cathepsins B and L [5], papain [6] and calpains 
specifically [7]. Hashida et al. reported the in vivo 
mechanisms of inhibition of cathepsin B and L by E-64 
and its derivatives [8,9]. But E-64 and its derivatives are 
not, however, selective inhibitors of cathepsins B and L 
either in vitro or in vivo. As specific inhibitors of the 
various cysteine proteinases are required for clarifying 
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cathepsin L, EC 3.4.22,15; calpain, EC 3.4.22.17 
the individual roles of these cysteine proteinases, the 
main aim of this study was to find a specific inhibitor of 
cathepsin B. X-ray crystal structure analysis of  papain 
and the papain-E-64;¢- complex [10], together with 
those of previous extensive studies on E-64 [4,5] and its 
derivatives [6,11,12] showed that an L-trans.epoxy- 
succinic acid group is advantageous m design of an in- 
hibitor that can distinguish cathepsin B from eathepsins 
H and L and calpains. Therefore, we designed new L- 
trans.epoxysuccinyl peptides that could fit the active 
site of cathepsin B, and developed two new selective 
inhibitors of cathepsin B, compound CA-030 N-(L-3. 
trans.ethoxycarbonyloxirane- 2-carbonyl)-L-isoleucyl- 
L-proline and compound CA-074 {N.(L-3.trans-propyl- 
carbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline. 
The present paper reports the selective inhibitory ac- 
tivities of these new epoxysuccinyl peptides on cathep- 
sin B in vitro. 
2. MATERIALS AND METHODS 
2.1, Materials 
All derivatives of E.64 were synthesized in our laboratory by the 
method escribed previously [13] with some modifications. They were 
fully characterized,by IR, proton NMR and fast atom bombardment 
MS and gave single spots on TLC, 
Rat liver cathepsins B, H and L were purified asdescribed previous- 
ly [5,14,15] with additional purification steps of HPLC on TSK gel 
G3000 SW (Tosoh) and Con A.Sepharose, Calpain II from porcine 
kidney was purchased from Nakarai Tesque, Kyoto, Japan. Z-Phe.. 
Arg-MCA, Z.Arg-Arg.MCA and Arg-MCA were from the Peptide 
Institute Inc., Osaka) Japan. 
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T~bl¢ I 
IC1= va!u~ of ~pos>'~u,:~inyl pep~lde dwivattv¢i rof ¢~1¢ir~¢ protein~w~ 
I¢'~= (.nMl 
Compound Structure C~lh~psln C~ip~ir~ It
B L tl 
I (CA.O)0) EtO.tES-I le.Pro.OH 2,2.# 32 000 240 000 .00 O00 
2 EtO.tES.Pro,Pro,OH 2~.0 4"/000 I 000 000 200 000 
3 EtO.tES-TI~r-II¢,O[-I I )J 540 000 I 000 000 200 000 
E.64.C HO.IES.Le~.t.iAA 3.36 O.O9 I 640 ) 000 
IES, L,trans,epoxysueeinyl; IAA, i~,oamnylamide 
2,2. Methods 
2,2.1. Delemtination of  lnhthi{or.v activities, The inhibitory a~:- 
tivities of new compound~ prepared in this study are d~own as thdr 
50% Inhibitory concentrations tiC,o) nnd their specifichies as relative 
IC~a values, 
2,2.2, Assays of cathepsins B, H tmd L, Fordet=rminationoflC.~. 
values, the activity of each cathepsm was adjusted toO.:] U (I U ofen- 
zyme activity is defined as that releasing, 1 nmol of 
7-amino.4-methylcoumarin per rain at 37"C). Cathepsin activities 
were assayed at pH 5.5 with Z-Arg-Arg-MCA as substrate for cathep- 
sin B, Arg.MCA for catllepsin H and Z-Phe-ArI~I-MCA for eathepsin 
L by the method of Barrett and Kirschke [16}, The reaction was in. 
itiated by addition of substrate (10 uM final concentration) after 
preincubation with the test compound for 3 lain a t  37"C. The 
fluorescence of the liberated ?.amino-4.mettWIcoumarin was 
measured in a Hitachi fluo,'es~,:nce spectrometer, naodel 650-10S 
equipped with a recorder, Emission at 460 nm was measured with ex- 
citation at 370 am, 
2,2.3. Assay ofcalpain, Calpain il (15/~g/tube) was assayed with 
0,24% alkaline-denatured casein as substrate atpH 7,5 by the method 
of lshiura et al, [t7], After preincubatlon with the test compound for 
5 minat 30°C, the reaction was started by adding CaCI2 at a final con- 
centration of 5 raM, After 20 rain the reaction was stopped by adding, 
10% Irichloroacetic a id solution, The mixture was then centrifuged, 
and the absorbance at 280 nm of the supernatant was measured in a 
Hitachi spectrophotometer, model U3210, 
3. RESULTS AND DISCUSSION 
Recent X-ray crystal structure analyses by two 
separate groups [10,18] indicated that E-64 and E-64.c 
bind to S subsites of papain. Therefore, in a computer- 
simulated study, epoxysuccinyl peptides such as E-64 
were also assumed to bind to S subsites of cathepsin B. 
Of tile compounds designed on the basis of this 
hypothesis, compounds I, 2 and 3, shown in Table 1, 
were found to be much stronger inhibitors of cathepsin 
B, but much weaker inhibitors of cathepsins L and H 
and calpain I1 than E-64.e. The common structures of 
these 3 compounds are a free carboxyl group at the C- 
terminal of the peptide and an ethyl ester group in the 
oxirane ring. Of these compounds, compound i 
(CA-030), which was the strongest inhibitor of cathep- 
sin B, was further modified focusing on these common 
structures. 
First, we converted the carboxyi group of proline to 
an amide group, an ester group, a hydroxymethyl group 
or a h.~rdrogen atom. As shown m Table II, the in- 
hibitory activities of these compounds 4-7 on cathepsin 
B were much weaker than that of compound 1 (CA-030) 
with a carboxyl group, suggesting that the carboxyl 
group is necessary for inhibition of cathepsin B. 
Next, we replaced the ethyl ester group in the oxirane 
ring by a carboxyl group or other ester groups. As sum- 
marized in Table III, compounds 8 (CA-028) and 9, 
with a carboxyl group and a methyl ester group, respec- 
tively, had weaker inhibitory activities and lower 
specificities for cathepsin B than compound ! 
(CA-030), but compounds 10-12 with bulky alkyl ester 
groups, such as isopropyl, isobutyl and cyclohexyl ester 
Table 11 
lCso values and relative lCso values of CA-030 derivatives for cysteine proteinases 
EtO.tES-IIe-N--R 
Compound R 
lCso (nM) 
Cathepsin Calpain 11 
B L H 
Relative ICso 
Cathepsin 
B:  L :  H 
I (CA-030) COOH 
4 CONHz 
5 COOMe 
6 CH2OH 
7 H 
2.28 32 O0O 240 00O 200 000 1: 14 000: 
5600 18 000 112 000 200 000 1: 3: 
4100 18 300 10 900 200 000 1: 4: 
6300 18 000 43 000 200 000 1: 3: 
2500 20 500 57 000 200 000 1: 8: 
105 000 
20 
3 
7 
23 
tES, L-truns.epoxysuccinyl 
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3'able III 
IC~,. ~tahl¢~ mid rCI~ll~¢ ICJ~ ~I~0 or {~A..O~O dcrivctllv¢~ for ¢yslrh~¢ prol¢i~s¢~ 
IC,~ taM) Relative IC~a 
i r  t i - - ~  - -  
Compound g Cath~p~ln Calp~in I I Calheptln 
. . . .  r j t t  J • 
B L H B :  L: H 
1i tCA.021~} H 30.4 
9 Me 20.0 
I tCA.030} F.z 2,211 
IO t.Pr 1,4~ 
t |  |.Bu 1.41 
12 ¢.H¢.~ I. I1 
IES. L.tmns.eposysueelnyl: I.Pr, |,opropyh i.Bu, tsobutyl; ¢.lqes, ey¢lohesyl 
~30 IS 400 1t2 000 I: I';: 300 
;2 460 40 17100 200 00G I : 120: 2 000 
32 000 240 000 200 000 I : 14 o00 105 00o 
27 ~00 46 000 100 000 I: 19 000: ~12 000 
22300 ~8000 20001}0 I: 16000: 41000 
$600 19000 200000 I: $000: 17000 
groups,  caused strong inhibition of  cathepsin B. These 
compounds also showed marked specificity for cathep- 
sin B, although compound 12 with a cyclohexyl ester 
group, showed lower ability to distinguish between 
cathepsins B and L than the other compounds. Judging 
by comparison of compounds 8 (CA-028), 9 and 1 
(CA.030), the presence of  a bulkier ester group than 
ethyl ester in trans.epoxysuccinic acid seemed indispen- 
sable for specific inhibition of cathepsin B, However, 
when these compounds are given to animals, they arc 
probably readily hydrolyzed like E-64-d, one of the 
E-64 analogs [19]. 't'laererore, to obtain analogs that 
were stable in r ive,  we examined the effect o f  replacing 
the ethyl ester group of compound 1 (CA-030) by  
various amide groups that should be more resistant o 
hydrolysis than ester groups. As shown in Table IV, 
replacements of the esters by the corresponding amides 
did not affect the specific inhibitory activities against 
cathepsin B, except in the case of compound 13, the 
diethyl amide derivative. The amide derivatives seemed 
to have somewhat weaker inhibitory activities than the 
corresponding ester derivatives, but considerably higher 
specificities for cathepsin B, Of  these corn pounds, corn, 
pound 16 (CA-074), the n.propylamide derivative, 
showed the highest inhibitory activity and specificity 
for cathepsin B. This compound specifically inactivated 
cathepsin B in rats in r ive  as expected; Details of its in- 
hibitory activity in rive are described by Towatar i  et al, 
[201. 
The computer simulation study indicated the 
presence of  a fairly large pocket around the thiol group 
of  the active site o f  cathepsin B. Its presence may 
distinguish cathepsin B from other cysteine proteinases. 
Compounds uch as CA-030 with ethyl ester group and 
CA-074 with n.propylamide group may fit into this 
pocket and strongly inactivate cathepsin B, but hardly 
affect other cysteine proteinases. 
CA-030 and CA-074 are the first compounds found 
Table IV 
lCso values and relative ICs0 values of CA.030 derivatives for cysteine proteinascs 
R.tES.IIe-Pro.OH 
ICed (aM) 
Compound R Cathepsin Calpain lI 
B L H 
Relative ICso 
Cathepsm 
B:  L :  H 
13 EtzN 2080 180 000 1 000 000 200 000 1: 8"/: 480 
!4 EtNH 6.88 186 000 I 000 0120 200 000 1: 2"/000: 145 000 
15 i.PrNH 4.64 260 000 I 000 000 200 000 1: 56 000: 216 000 
16 (CA-074) n-PrHN 2.24 172 000 420 000 200 000 I: 77 000: 188 000 
17 i-BuNH 1.78 [22 000 92 000 200 000 1: 69 1300: 52 000 
18 n.BuNFI 2.26 106 000 220 000 200 000 1: 47 COO: 97 000 
19 i-AmNH 2.40 68 000 238 000 200 000 1: 28 000: 99 000 
20 n.AmNH 3.16 51 000 200 000 200 000 1: 16 000: 63 000 
21 n-He•NH 3.92 38 000 214 000 200 000 1: 10 000: 55 000 
22 PhCH2NH 5.48 51 200 192 000 100 000 1: 9 000: 35 000 
23 PhNH 12.2 35 000 190 000 20{) 000 1: 3 000: 16 000 
24 c.He×NH 2.20 20 000 33 000 200 000 1: 9 000: 15 000 
tES, L=trans-epoxysuccinyl; i-Pr, isopropyl; i-Bu, isobutyl; n.Pr, n-propyl; n-Bu, n-butyl; i-Am, isoamyl; n-Am, n-arayl; n.He)c, n-hexyl; Ph, 
phenyl; c-Hex, cyclohc×yl 
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to inh ib i t  emhepsin B selectively in v i t ro ,  In in v i t ro  
studies, these cornpound~ should be u~erul for  [he |den- 
t i t | cat ion  or  ca|hepsin B and the study o f  inh ib i t ion  
ch~tr~c(eristics o f  eysleine prote~ses, 
Hek.o~#¢d~em~ntx: We ~hank Dr K.ntltiko Kil~mur~t and ~lr 
$i~eyuki $.mlY~ for g~¢f.I sul~esiio~ a~d Nli~t Hilov ,Ar~| f~r 
l¢~hnic~tt as~islance. 
REFERENCES 
[ I ] K~lunuma, N, (19ti91 in: RBC: C~II Btolo|y Reviews (E, Knee:hi 
.rid $. Gri~olia. ¢d~1 Vol. 20, pp. ~:%(Sl, Sprinser. llerltn, 
IZl Kir$chke, H,, Kembh~vi, A.A., Bohley, P, and El~rreu, A,J. 
(19821 Blochem, J. 201. ~67-~12. 
{3) M.,son, R,W,. Johnson, D,A,. B~rretl. A J, ~t,¢l Chapm~r~, 
H,A, (1986) Biochem, J. 2~3,925-929, 
[4] Httnada. g,, T~trnal, M.. Yam.l~idd, M,, Ohmura. 5 .  $awad~. 
J. and "ra.aka. I. (19~8) Ailric, Biol, CItem, 42, $23=$21~. 
[5] Towalarl, T,, Tltmika, K.. Yoshikaw~t, D..r id K=l|tll~tlltli~. N. 
(1978) J. Bioehem. R4, 6~9-6`/I. 
(6) Tam=t|, M., tl~nad=t, K~, Ad~tehi, T,. Oiluma, K,, Kad~iwai~i, K , 
Onl~lra, S. and Ohzeki, M. (1981) J, Bioehet|'~, 90. 255=2~7, 
{'/] Sugil~. El,, l~hit~ra, $., Su=uki. K, and Imahori, K. 0980) J. 
Biocl~eln, 8`/, 339-341. 
[8] H~tshida, S,, Tow=t|ari, T., Komlnami, E, And Ka|0numn. N 
(1990) J, Biochem. 88, 1805-181 I, 
I'll l,l~hldct. $.. K~min~mi. E. and Kil,n,m~. N. Hi|I} J. 
l~li~hcm. 91. I]'~3=I]I~. 
It 0| M~l~umolo. K,, Y,mamoto. D.. {~hi~hi. H.. T~n~s~. K.. hhid~. 
T.. Inome. M.. ~d~loms.. T.. Kil~mur~. K. and Mi~un~, H. 
tlPlt91 FEB~ L l l l .  ~4~$. 19"/~lJO. 
! l l l  $t~had~. K.. T~m~t. ~,I.. hloflmolo. ~.  Ad~.ht. T.. t~hmura. 
~.. S~lw~d~. J. ~ind TNo~k~t. i. (199#] Alrl¢. Biol. ~:h~m. 42. 
ItH B~rr~,. ^ J . .  K~mbh~svt. A.A.. Brown. M.A.. Kir~hk~'. H.. 
Knt¢lh#. C.(-L. T~m~i. M. ~nd Hanccda. K. (19e2) Blo~h~m. J. 
201~ Ili?~ 19B. 
(I)| Tamal, M., Yok~o, C,, ~,lural~. M,, Oilum;~, K.  ~;o1~. K,, ~.lo, 
E. z~nd Kam~ok,. Y. (19~'/) Chem. Pl~,rm. Bull. 3~. 1(Y9~-1104. 
tl4) Klrwhke, H., [~l~n~r, $,, Wi~d~t~lld~r~, B., An~oflle, ~.. 
Bohiey. P. ,rid H~n~on. f l  (1997) A¢llS Blot. Med. G~rm. 36. 
[I ~) TOwlHart. T. and Ka|~.lflorl~a. N (1971~) Bto~hem. Bioph~. Re~. 
Commun, 83, $1~=~20. 
[16] B;~rrel|, A.J. ~n¢! Kirsehke, H. (191(11 Melhod~ E.~ymoi. 10, 
F:l~-J61. 
[|`/) I~hiurn, .~., Murofusht. H,, S.~(~ki, K, ~nd Im~hori, K, (1998) 
J, Blochem. (Tokyo) ~4, 22;S-230. 
[i8] Vetrughe~e, K.I,. Ahmed, F,P,, C~r©y, P,R,, H~sn=in, 5,, 
Huber, C,P. ~n(l Slorer, A,C. (1989) Bioehen~lslry 28, 
|~O0-1332. 
[19] Tamai, M., Mal~umolo, K., Omura, $., Ko)'ama. 1,, Ozawa, Y. 
and H~nnda, K, (1986) J, Pharmacobio.Dyn, 9, 6"/2-6T/, 
[20] Towmari, T,, Niknwa. T., Murata, M., Yokoo, C,. Tam=~i, M,. 
Hanada, K, and Katunum.'l, N. (|991) FEBS Left, 280.31 !-315, 
310 
